Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: A rapid thaw in biopharma funding reignites explosive demand for bioproduction and clinical research.
Prolonged Biopharma Funding Winter: Extended depression in early-stage biotech funding permanently impairs the growth trajectory of the life sciences solutions segment.
Thermo Fisher Scientific is the dominant, scale-advantaged player in life sciences tools and diagnostics. Its comprehensive portfolio, deep customer relationships, and proven M&A integration engine drive consistent cash flow generation and mid-single-digit organic growth over the long term. However, elevated debt levels and the sheer scale of operations are expected to naturally decelerate its historical M&A-driven compounding trajectory.
Thermo Fisher Scientific is the dominant, scale-advantaged player in life sciences tools and diagnostics. Its comprehensive portfolio, deep customer relationships, and proven M&A integration engine drive consistent cash flow generation and mid-single-digit organic growth over the long term. However, elevated debt levels and the sheer scale of operations are expected to naturally decelerate its historical M&A-driven compounding trajectory.
High Switching Costs
Unmatched Scale
Accelerating biopharma R&D spend, robust FDA approvals, and strong academic funding drive demand for tools and bioproduction.
Hold. A magnificent business trading precisely at our structurally-adjusted fair value.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
A stress test assuming flat organic growth for three years and a terminal multiple contraction to 15x yields a downside value near $384. This scenario materializes if biopharma R&D budgets are slashed and pricing power evaporates.
High Switching Costs
Unmatched Scale
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $9.2B after capex $1.5B, with terminal value at 65.7% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If organic growth exceeds 5% and margins expand, expect a multiple re-rating towards internal valuation cross-checks $620.
If organic growth exceeds 5% and margins expand, expect a multiple re-rating towards internal valuation cross-checks $620.
If organic growth exceeds 5% and margins expand, expect a multiple re-rating towards internal valuation cross-checks $620.
If organic growth exceeds 5% and margins expand, expect a multiple re-rating towards internal valuation cross-checks $620.
Maturing consolidation phase; major players have scaled, shifting focus to bolt-on tech acquisitions and optimizing existing footprints.
Accelerating biopharma R&D spend, robust FDA approvals, and strong academic funding drive demand for tools and bioproduction.
Rising interest rates choke off venture capital for early-stage biotech, causing inventory destocking and delayed capital equipment purchases.
Maturing consolidation phase; major players have scaled, shifting focus to bolt-on tech acquisitions and optimizing existing footprints.
Market weight or slight underweight. The current valuation adequately prices in the base case recovery.
Trim positions approaching $600 as the valuation would require heroic assumptions regarding permanent M&A premium extrapolation.
Hold. The risk/reward is balanced, with structural debt and scale headwinds offsetting near-term cyclical recovery prospects.
internal valuation cross-checks at $620 implicitly extrapolates peak M&A premiums permanently. We apply a strict moat-fade mechanic, recognizing that a $176B market cap entity cannot acquire its way to double-digit growth forever.
Hold. The risk/reward is balanced, with structural debt and scale headwinds offsetting near-term cyclical recovery prospects.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
A sustained freeze in biotech funding creates a multi-year drag on top-line growth. Heavily leveraged from past acquisitions, TMO struggles to find accretive targets, breaking the compounding thesis and compressing multiples.
Extended depression in early-stage biotech funding permanently impairs the growth trajectory of the life sciences solutions segment.
Elevated debt levels ($31B+) and higher interest rates restrict accretive acquisitions, eliminating the historical EPS compounding mechanism.
A major acquisition fails to deliver projected synergies, destroying ROIC and leading to a significant multiple de-rating.
The five developments that would weaken our investment case.
Consecutive periods of contracting core revenue indicate broad-based biopharma spending freezes and lab equipment demand softness, threatening baseline top-line expansion assumptions and operating leverage.
Current:0.1% revenue growth for the period ended 2024-12-31
Alert if< 0.0% organic revenue growth for two consecutive quarters
Persistent gross profitability erosion signals loss of pharmaceutical manufacturing pricing power and unfavorable product mix shifts toward lower-margin commoditized laboratory supplies, reducing cash generation capabilities.
Current:41.3% for the period ended 2024-12-31
Alert ifContraction of > 100 basis points year-over-year in any fiscal year
Excessive leverage constraints block accretive bolt-on mergers and acquisitions, forcing cash flows toward debt service rather than opportunistic capital deployment and compounding earnings growth.
Current:Elevated debt levels ($31B+) as of 2026-05-09
Alert if> 3.5x across two consecutive quarters
A sustained drop in cash conversion undermines high reported accounting quality, signaling rising uncollected receivables or inventory build-ups that constrain free cash available for debt paydown.
Current:1.368 as of 2026-05-09
Alert if< 1.00 for two consecutive fiscal years
Lowering baseline organic growth targets signals structural maturation across life sciences end-markets, forcing an equity multiple de-rating as investors recalibrate terminal valuation and compound earnings expectations.
Current:Mid-single-digit long-term target active as of 2026-05-09
Alert ifReduction of long-term organic growth target to < 4.0% in any annual guidance update
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
A rapid thaw in biopharma funding reignites explosive demand for bioproduction and clinical research. Unmatched scale allows TMO to capture outsized market share while driving unprecedented margin expansion.
TMO returns to steady, mid-single-digit organic growth. While free cash flow generation remains stellar, the sheer scale of the business and elevated debt load naturally decelerate the historical pace of M&A-driven compounding.
Warning level: < 0.0% organic revenue growth for two consecutive quarters. Consecutive periods of contracting core revenue indicate broad-based biopharma spending freezes and lab equipment demand softness, threatening baseline top-line expansion assumptions and operating leverage.
Warning level: Contraction of > 100 basis points year-over-year in any fiscal year. Persistent gross profitability erosion signals loss of pharmaceutical manufacturing pricing power and unfavorable product mix shifts toward lower-margin commoditized laboratory supplies, reducing cash generation capabilities.
Warning level: > 3.5x across two consecutive quarters. Excessive leverage constraints block accretive bolt-on mergers and acquisitions, forcing cash flows toward debt service rather than opportunistic capital deployment and compounding earnings growth.
Warning level: < 1.00 for two consecutive fiscal years. A sustained drop in cash conversion undermines high reported accounting quality, signaling rising uncollected receivables or inventory build-ups that constrain free cash available for debt paydown.
Warning level: Reduction of long-term organic growth target to < 4.0% in any annual guidance update. Lowering baseline organic growth targets signals structural maturation across life sciences end-markets, forcing an equity multiple de-rating as investors recalibrate terminal valuation and compound earnings expectations.
| $39.21B |
| $44.92B |
| $42.86B |
| $42.88B |
| — |
| +3.0% |
| Gross profit | $19.64B | $18.97B | $17.10B | $17.70B | — | -3.4% |
| Operating income | $9.38B | $8.56B | $7.67B | $8.43B | — | -3.5% |
| Net income | $7.73B | $6.95B | $6.00B | $6.34B | — | -6.4% |
| EPS (diluted) | — | $17.63 | $15.45 | $16.53 | $17.74 | +0.2% |
| EBITDA | $11.97B | $11.94B | $11.08B | $11.54B | — | -1.2% |
| R&D | $1.41B | $1.47B | $1.34B | $1.39B | — | -0.4% |
| SG&A | $8.01B | $8.99B | $8.45B | $8.60B | — | +2.4% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 42,879,000,000 |
|---|---|
| Cost of revenue | 25,177,000,000 |
| Gross profit | 17,702,000,000 |
| Operating expenses | 9,985,000,000 |
| Operating income | 7,717,000,000 |
| Non-operating items and tax | -1,382,000,000 |
| Net income | 6,335,000,000 |
| Total assets | 97,321,000,000 |
|---|---|
| Cash | 4,009,000,000 |
| Current assets | 22,137,000,000 |
| Total liabilities | 47,649,000,000 |
| Current liabilities | 13,332,000,000 |
| Shareholders’ equity | 49,585,000,000 |
Point-in-time financial data used in the 2026-05-09 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | 39.2B | 12B | 7.7B | 9.3B | 6.8B | 2.5B | 2.6B | 230M | 2B | 395M | 8.9B | — | — | — | — | 4.5B | 34.9B | 26.1% | — | — | — |
| 2022-12-31 | 44.9B | 11.9B | 7B | 9.2B | 6.9B | 2.2B | 3.4B | 307M | 3B | 455M | 654M | — | — | — | — | 8.5B | 34.5B | 18.9% | — | — | — |
| 2023-12-31 | 42.9B | 11.1B | 6B | 8.4B | 6.9B | 1.5B | 3.4B | 278M | 3B | 523M | -155M | — | — | — | — | 8.1B | 34.9B | 17.1% | — | 7.9% | — |
| 2024-12-31 | 42.9B | 11.5B | 6.3B | 8.7B | 7.3B | 1.4B | 3.1B | 301M | 4B | 583M | -2.4B | — | — | — | — | 4B | 31.3B | 18.0% | — | 8.0% | — |
TMO trades at 17.3x forward earnings against a peer median of 18.8x; EV/EBITDA of 19.2x against a peer median of 17.9x; 6 peers.
| Initiate or add below $415 (our discounted earnings support level) offering an attractive margin of safety. |
| IDEXX Laboratories Inc. |
| 34.7x |
| 10.2x |
| 30.1x |
| 72.9% |
| 31.8% |
| WAT | Waters Corporation | 21.4x | 9.1x | 27.0x | 5.2% | 11.7% |
| A | Agilent Technologies Inc. | 17.6x | 4.6x | 17.9x | 19.9% | 22.9% |
| NTRA | Natera Inc. | -324.1x | 13.6x | -111.6x | -14.3% | -3.4% |
